KDR and gastric cancer: Given the limited benefits of conventional chemotherapy for metastatic GC, the additions of human epidermal growth factor receptor-2 (HER-2)-targeted therapy, anti-vascular endothelial growth factor receptor 2 (VEGFR2)-targeted antibody, and immune checkpoint inhibitors are under investigations [3].